1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Euronext Paris  -  10:24 2022-08-19 am EDT
1.266 EUR   -1.40%
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeypox Assay in Response to the Recent Outbreak of the Virus in Non-Endemic Countries

06/28/2022 | 02:00am EDT

Novacyt announced the launch of its research-use-only (RUO) polymerase chain reaction (PCR) monkeypox assay in response to the recent outbreak of the virus in non-endemic countries. The launch of this assay expands Novacyt's genesig® real-time PCR diagnostic product portfolio and is in line with the company's strategy to maintain its position as a global first responder in infectious diseases. Monkeypox is a rare viral disease, which predominantly occurs in Central and Western Africa.

The monkeypox virus is zoonotic meaning transmission is primarily between animals and humans, but human-to-human transmission can also occur, through contact with skin lesions, body fluids and respiratory secretions of infected animals or humans. Clinical presentations in humans are similar to smallpox with fever, headache, swollen lymph nodes, fatigue, and muscle aches along with characteristic pox lesions. Novacyt's RUO monkeypox assay has been developed in two forms, genesig® easy and genesig® advanced, for detection of the virus genome (both West African and Central African variants).

Both forms analyse DNA extracted from serum, lesion exudate, or scab samples from human or animal species. The genesig® advanced assay is designed to be used with any open test platform, including Novacyt's MyGo instruments, whilst the genesig® easy assay is suitable for use on the Company's q16 and q32 instruments. The advanced assay is quantitative if run alongside the recommended standard curve but can also be run without one and still give a qualitative result.

The easy kit (q16 and q32 only) does not need a standard curve, instead software analyses the results of the sample and control to give a semi-quantitative result.


© S&P Capital IQ 2022
All news about NOVACYT
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-P..
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
07/28Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay
CI
07/21NOVACYT : Results of Annual General Meeting
PU
07/21NOVACYT : AGM Investor Presentation
PU
07/15Novacyt - Approval of exsig COVID-19 Direct test in the UK under CTDA legislation
AQ
07/15UK Watchdog OKs Novacyt's exsig COVID-19 Direct Test
MT
07/15Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK
CI
07/07NOVACYT : Half-year results
CO
More news
Financials
Sales 2021 95,8 M - -
Net income 2021 -9,73 M - -
Net cash 2021 99,9 M - -
P/E ratio 2021 -31,3x
Yield 2021 -
Capitalization 90,7 M 91,9 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,19x
Nbr of Employees 276
Free-Float 94,8%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Paul Oladimeji Group Head-Research & Development
Bryan Close Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-70.68%92
GILEAD SCIENCES, INC.-10.23%81 694
VERTEX PHARMACEUTICALS34.01%75 473
REGENERON PHARMACEUTICALS, INC.-1.06%66 800
MODERNA, INC.-40.94%58 680
LONZA GROUP AG-24.63%44 689